Simulated Driving Changes in Young Adults With ADHD Receiving Mixed Amphetamine Salts Extended Release and Atomoxetine.

Author(s): Kay GG, Michaels MA, Pakull B

Affiliation(s): Cognitive Research Corporation.

Publication date & source: 2008-09-24, J Atten Disord., [Epub ahead of print]

Publication type:

Background: Psychostimulant treatment may improve simulated driving performance in young adults with attentiondeficit/hyperactivity disorder (ADHD). Method: This was a randomized, double-blind, placebo-controlled, crossover study of simulated driving performance with mixed amphetamine salts-extended release (MAS XR) 50 mg/day (Cohort 1) and atomoxetine 80 mg/day (Cohort 2) in young adults with ADHD. Results: Adults aged 19 to 25 years with ADHD (N = 19) who were administered MAS XR significantly improved overall simulated driving performance versus placebo up to 12 hours after dosing. In contrast, there were no statistically significant differences in simulated-driving-performance scores between atomoxetine and placebo. At endpoint, MAS XR reduced ADHD Rating Scale scores >/= 30% in 80% of subjects, whereas atomoxetine achieved this level of improvement for 40%. Limitations: Small sample size and use of simulated driving may limit generalizability of the findings. Conclusion: MAS XR in young adults with ADHD yields significant improvements in simulated driving performance and ADHD symptoms. (J. of Att. Dis. XXXX; XX(X) xx-xx).